Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Bhurani, M; Admojo, L; van der Weyden, C; Twigger, R; Bazargan, A; Quach, H; Zimet, A; Coyle, L; Lindsay, J; Radeski, D; Hawkes, E; Kennedy, G; Irving, I; Gutta, N; Trotman, J; Yeung, J; Dunlop, L; Hua, M; Giri, P; Yuen, S; Panicker, S; Moreton, S; Khoo, L; Scott, A; Kipp, D; McQuillan, A; McCormack, C; Dickinson, M; Prince, HM

Author(s): Bhurani, M; Admojo, L; van der Weyden, C; Twigger, R; Bazargan, A; Quach, H; Zimet, A; Coyle, L; Lindsay, J; Radeski, D; Hawkes, E; Kennedy, G; Irving, I; Gutta, N; Trotman, J; Yeung, J; Dunlop, L; Hua, M; Giri, P; Yuen, S; Panicker, S; Moreton, S; Khoo, L; Scott, A; Kipp, D; McQuillan, A; McCormack, C; Dickinson, M; Prince, HM;
Details: Publication Year 2021-02,Volume 62,Issue #2,Page 330-336
Journal Title: Leukemia & Lymphoma
Publication Type: Research article
Abstract: We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.
Keywords: Aged; Aminopterin/analogs & derivatives; Australia/epidemiology; Humans; *Lymphoma, T-Cell/drug therapy; *Neoplasm Recurrence, Local/drug therapy; Retrospective Studies; Treatment Outcome; Pralatrexate; T-cell lymphoma; cutaneous T-cell lymphoma; mucositis; peripheral T-cell lymphoma
Department(s): Haematology; Surgical Oncology
PubMed ID: 33026266
Publisher's Version: https://doi.org/10.1080/10428194.2020.1827241
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-06-06 07:51:53

Last Modified: 2025-06-06 07:57:04